newsfilter
← Latest News
GlobeNewswire·

Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024